{"id":"triple-antigen","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability or fussiness"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL2107987","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Triple Antigen™ is a combination vaccine containing antigens from three infectious diseases, designed to elicit humoral and cellular immune responses against all three pathogens in a single formulation. By presenting multiple antigens, it provides simultaneous immunization and protection against three diseases, reducing the number of injections needed compared to separate vaccines.","oneSentence":"Triple Antigen™ is a vaccine that stimulates immune responses against three disease antigens simultaneously to provide combined protection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:06.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immunization against diphtheria, pertussis, and tetanus (DPT)"}]},"trialDetails":[{"nctId":"NCT05274451","phase":"PHASE1","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","status":"TERMINATED","sponsor":"Lyell Immunopharma, Inc.","startDate":"2022-03-29","conditions":"Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer","enrollment":57},{"nctId":"NCT03175666","phase":"PHASE1, PHASE2","title":"QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":"Hepatitis B","enrollment":308}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":81,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DTPwcsl vaccine"],"phase":"phase_3","status":"active","brandName":"Triple Antigen™","genericName":"Triple Antigen™","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Triple Antigen™ is a vaccine that stimulates immune responses against three disease antigens simultaneously to provide combined protection. Used for Immunization against diphtheria, pertussis, and tetanus (DPT).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}